Gainers

• ENvue Medical (NASDAQ:FEED) shares increased by 59.4% to $2.28 during Tuesday's regular session. The company's market cap stands at $1.5 million.
• Sol-Gel Technologies (NASDAQ:SLGL) stock increased by 33.68% to $88.5. The company's market cap stands at $184.4 million. As per the news, the Q4 earnings report came out 3 days ago.
• Quantum BioPharma (NASDAQ:QNTM) stock moved upwards by 25.04% to $3.88. The market value of their outstanding shares is at $11.9 million.
• CollPlant Biotechnologies (NASDAQ:CLGN) shares increased by 18.61% to $0.72. The market value of their outstanding shares is at $7.7 million.
• YD Bio (NASDAQ:YDES) stock increased by 17.56% to $7.63. The market value of their outstanding shares is at $457.6 million.
• Assertio Holdings (NASDAQ:ASRT) shares rose 15.46% to $16.16. The company's market cap stands at $90.2 million.

Losers

• Outlook Therapeutics (NASDAQ:OTLK) shares decreased by 37.8% to $0.2 during Tuesday's regular session. The company's market cap stands at $23.5 million.
• ImmunityBio (NASDAQ:IBRX) stock declined by 24.68% to $7.08. The company's market cap stands at $9.6 billion.
• Achieve Life Sciences (NASDAQ:ACHV) shares decreased by 22.77% to $3.13. The market value of their outstanding shares is at $215.5 million. The company's, Q4 earnings came out today.
• Artelo Biosciences (NASDAQ:ARTL) shares decreased by 22.2% to $5.96. The company's market cap stands at $5.4 million.
• bioAffinity Technologies (NASDAQ:BIAF) stock declined by 21.78% to $3.7. The company's market cap stands at $21.2 million.
• Serina Therapeutics (AMEX:SER) shares decreased by 20.64% to $2.5. The company's market cap stands at $33.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.